Organization
Department of Radiation Oncology
26 abstracts
Abstract
Evaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial.Org: Department of Neurosurgery, Prince of Wales Hospital, Department of Radiation Oncology, Baptist Health South Florida, Perelman School of Medicine, Department of Radiology,
Abstract
WITHDRAWN: A phase II study analyzing pre-operative stereotactic radiosurgery followed by resection for patients with 1-4 brain metastases.Org: Simon Cancer Center, Indianapolis, IN, Department of Radiation Oncology, Indiana University School of Medicine, Department of Clinical Radiology and Imaging Sciences,
Abstract
LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).Org: Sir Peter MacCallum Department of Oncology, St. Vincent's Hospital, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Department of Radiation Oncology, St. Vincent's Medical School,
Abstract
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.Org: Sun Yat-sen University Cancer Centre, Collaborative Innovation Centre for Cancer Medicine, Hunan Cancer Hospital, Department of Radiation Oncology, Affiliated Hospital of Guizhou Medical University,
Abstract
Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.Org: Guangdong Lung Cancer Institute, China National Biotec Group, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangzhou JOYO Pharma, Cancer Hospital,
Abstract
Disparities in outcomes among hospitalized unhoused patients with cancer in the US.Org: NYU Grossman School of Medicine, Department of Radiation Oncology, Tufts University School of Medicine, Memorial Sloan Kettering Cancer Center, Washington University School of Medicine in St. Louis,
Abstract
Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial).Org: University of Bielefeld, Medical University of Graz, Department of Radiation Oncology, University of Leipzig Medical Center, Comprehensive Cancer Center Central Germany,
Abstract
Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.Org: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer,
Abstract
A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091).Org: Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, The First People's Hospital of Foshan,
Abstract
A randomised, controlled, multicentre trial of imiquimod versus radiotherapy for lentigo maligna.Org: Melanoma Institute Australia, The University of Sydney, Chris O'Brien Lifehouse, Icon Cancer Centre, Faculty of Medicine and Health, The University of Sydney,
Abstract
RMS13: A phase II trial using risk adapted focal proton beam radiation and/or surgery with the addition of maintenance chemotherapy in intermediate risk rhabdomyosarcoma.Org: St. Jude Children's Research Hospital, Department of Radiation Oncology, University of Florida College of Medicine Jacksonville, Cook Children's Medical Center, Department of Radiation Oncology, University of Florida College of Medicine Jacksonville,
Abstract
CD8 radiomics signature to assess inter-lesion spatial heterogeneity and cold liver lesions in advanced non-small cell lung cancers treated with durvalumab.Org: Gustave Roussy Cancer Center, Department of Radiation Oncology, Université Paris-Saclay, UMR 1030, ImmunoRadAI,
Abstract
Immune related adverse events in patients with breast cancer and autoimmune disease treated with immunotherapy.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Massachusetts General Hospital, Department of Radiation Oncology, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA,
Abstract
A single center retrospective cohort study of patients with metastatic breast cancer and leptomeningeal disease: Updated survival data and subgroup analyses by breast cancer subtype.Org: University of California Irvine, UCSF Breast Care Center, UCSF Medical Center, Helen Diller Family Comprehensive Cancer Center, Department of Radiation Oncology,
Abstract
Patient-reported outcomes in N1 breast cancer: A phase III trial comparing whole-breast to whole-breast plus regional irradiation after taxane-based chemotherapy (KROG 1701).Org: Samsung Medical Center, Chonnam National University Medical School and CNU Hwasun Hospital, Asan Medical Center, Soonchunhyang University Hospital, Gil Medical Center,
Abstract
Sociodemographic differences in suicide/intentional self-harm among cancer survivors versus the general United States population.Org: University of Iowa College of Public Health, Henry Ford Health System, Department of Radiation Oncology, Washington University School of Medicine in St. Louis, Duke University Medical Center,
Abstract
Establishing a protocol to increase racial/ethnic minority enrollment on an active radiation oncology randomized clinical trial.Org: Johns Hopkins University School of Medicine, Johns Hopkins Bloomberg School of Public Health, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation,
Abstract
Radiosurgery to 5 or more newly diagnosed brain metastases in the systemic therapy era.Org: The University of Texas MD Anderson Cancer Center, New York City, Txinno Bioscience, Houston, TX, Brody School of Medicine at East Carolina University,
Abstract
Out-of-pocket cost modeling of adjuvant radiation therapy duration in standard-of-care treatment of glioblastoma across Medicaid and Medicare plans.Org: Case Western Reserve University School of Medicine, Department of Radiation Oncology, University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center,
Abstract
Phase I clinical trial of peposertib plus radiation in adults with newly diagnosed MGMT-unmethylated glioblastoma.Org: The University of Texas MD Anderson Cancer Center, Department of Neuro-Oncology, Department of Biostatistics & Data Science, Department of Radiation Oncology, University of California Irvine,
Abstract
High deductible health plans and survival among cancer survivors.Org: Department of Radiation Oncology, Washington University School of Medicine in St. Louis, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, Costs of Care, Boston, University of Minnesota Masonic Cancer Center, University of California, San Francisco,
Abstract
State mandatory paid medical leave policies and cancer stage at diagnosis in US adults.Org: Saint Louis University School of Medicine, Washington University School of Medicine in St. Louis, Memorial Sloan Kettering Cancer Center, American Cancer Society, Washington University School of Medicine,
Abstract
Survival outcomes associated with first-line PCV or temozolomide in combination with radiotherapy in IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma.Org: Paris Brain Institute (ICM), Service de Neurologie 2 Mazarin, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, AP-HP, Sorbonne Université, Lyon HCL,
Abstract
Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A phase III, prospective, randomised-controlled, multicenter clinical trial.Org: Department of Radiation Oncology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China, Department of Oncology, the Affiliated Hospital of North Sichuan Medical College, Nanchong, China, Department of Oncology, Wuzhou Red Cross Hospital, Wuzhou, China, Department of Radiation Oncology, Hainan General Hospital, Haikou, China, Department of Oncology, Liuzhou People's Hospital, Liuzhou, China,
Abstract
SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma.Org: UPMC Hillman Cancer Center, Mayo Clinic Rochester, Melanoma Institute Australia, University of Sydney and Sydney Cancer Centre, Chris O'Brien Lifehouse,
Abstract
Financial toxicity in patients with metastatic breast cancer on trastuzumab deruxtecan (T-DXd).Org: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, School of Social Work, The University of North Carolina at Chapel Hill, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, NYU Grossman Long Island School of Medicine, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center,